IVA Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of -- compared to Inventiva SA's net margin of 1.68%. Inventiva SA's return on equity of -- beat Cellectis SA's return on equity of -31.08%.

Inventiva SA has a consensus price target of $15.00, signalling upside risk potential of 210.57%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 63.27%. Given that Inventiva SA has higher upside potential than Cellectis SA, analysts believe Inventiva SA is more attractive than Cellectis SA.

Inventiva SA has a beta of 0.708, which suggesting that the stock is 29.184% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.823, suggesting its more volatile than the S&P 500 by 182.278%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. Inventiva SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, Inventiva SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 28.12x versus 5.49x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Inventiva SA has a consensus price target of $15.00, signalling upside risk potential of 210.57%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 133.35%. Given that Inventiva SA has higher upside potential than DBV Technologies SA, analysts believe Inventiva SA is more attractive than DBV Technologies SA.

Inventiva SA has a beta of 0.708, which suggesting that the stock is 29.184% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Inventiva SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Inventiva SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 28.12x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

EDAP TMS SA has a net margin of -- compared to Inventiva SA's net margin of -36.13%. Inventiva SA's return on equity of -- beat EDAP TMS SA's return on equity of -56.97%.

Inventiva SA has a consensus price target of $15.00, signalling upside risk potential of 210.57%. On the other hand EDAP TMS SA has an analysts' consensus of $5.83 which suggests that it could grow by 58.51%. Given that Inventiva SA has higher upside potential than EDAP TMS SA, analysts believe Inventiva SA is more attractive than EDAP TMS SA.

Inventiva SA has a beta of 0.708, which suggesting that the stock is 29.184% less volatile than S&P 500. In comparison EDAP TMS SA has a beta of -0.260, suggesting its less volatile than the S&P 500 by 126.03%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EDAP TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. EDAP TMS SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than EDAP TMS SA quarterly revenues of $16.2M. Inventiva SA's net income of -- is lower than EDAP TMS SA's net income of -$5.9M. Notably, Inventiva SA's price-to-earnings ratio is -- while EDAP TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 28.12x versus 1.96x for EDAP TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Inventiva SA has a consensus price target of $15.00, signalling upside risk potential of 210.57%. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 192.84%. Given that Inventiva SA has higher upside potential than Innate Pharma SA, analysts believe Inventiva SA is more attractive than Innate Pharma SA.

Inventiva SA has a beta of 0.708, which suggesting that the stock is 29.184% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.018, suggesting its less volatile than the S&P 500 by 101.755%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 28.12x versus 22.73x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.